Single Technology Appraisal at the UK National Institute for Health and Clinical Excellence

House of Commons Health Committee. National Institute for Health and Clinical Excellence. Volume I: report, together with formal minutes. London: The Stationery Office Limited, 2007 Barham L. Single technology appraisals by NICE: are they delivering faster guidance to the NHS? Pharmacoeconomics 2008; 26 (12): 1037–43 Kaltenthaler E, Tappenden P, Booth A, et al. Comparing methods for full versus single technology appraisal: a case study of docetaxel and paclitaxel for early breast cancer. Health Policy 2008; 87: 389–400 Rodgers M, Griffin S, Paulden M, et al. Alitretinoin for severe chronic hand eczema: a NICE single technology appraisal. Pharmacoeconomics 2010: 28 (5): 351–62 Towse A, Garrison Jr LP. Cant get no satisfaction? Will pay for performance help? Toward an economic framework for understanding performance-based risk-sharing agreements for innovative medical products. Pharmacoeconomics 2010; 28 (2): 93–102 MacLeod S, Mitton C. We know accurately only when we know little. Pharmacoeconomics 2010; 28 (2): 105–7 Menon D, McCabe CJ, Stafinski T, et al. Principles of design of access with evidence development approaches: a consensus statement from the Banff Summitt. Pharmacoeconomics 2010; 28 (2): 109–11 Stafinski T, McCabe CJ, Menon D. Funding the unfundable: mechanisms for managing uncertainty in decisions on the introduction of new and innovative technologies into healthcare systems. Pharmacoeconomics 2010; 28 (2): 113–42 McCabe CJ, Stafinski T, Edlin R, et al. Access with evidence development schemes: a framework for description and evaluation. Pharmacoeconomics 2010; 28 (2): 143–52 Mohr PE, Tunis SR. Access with evidence development: the US experience. Pharmacoeconomics 2010; 28 (2): 153–62 Briggs A, Ritchie K, Fenwick E, et al. Access with evidence development in the UK: past experience, current initiatives and future potential. Pharmacoeconomics 2010; 28 (2): 163–70 Bagust A, Greenhalgh J, Boland A, et al. Cetuximab for recurrent and/or metastatic squamous cell carcinoma of the head and neck: a NICE single technology appraisal. Pharmacoeconomics. In press National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal. London: NICE, 2008 Barbieri M, Hawkins N, Sculpher MJ. Who does the numbers? The role of third-party technology assessments to inform health systems’ decision-making about the funding of health technologies. Value Health 2009; 12: 193–201